Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Thursday, October 22, 2026

Back to today

From X

@StableBread 5 clicks

Fajasy on X

I went through every Boost Run $BRUN contract with disclosed terms to see how much of its $2.6B+ of total contract value (TCV) they cover. Cohere, the Canadian developer of AI models for businesses and governments, agreed on September 30, 2026, to pay $BRUN $525.6M over the agreement’s term for $NVDA’s GB300 NVL72 racks, each with 72 Blackwell Ultra GPUs. Part of the $525.6M is a prepayment $BRUN hasn’t disclosed. But if we follow the 22% average $BRUN says its prepayments run, the prepayment would be ~$116M. Each rack’s term runs 60 months, and the first racks should start in Q2 2027. Cohere can terminate and get back everything it prepaid if it hasn’t accepted a minimum number of racks by July 15, 2027. $BRUN has disclosed terms for seven contracts, and the two largest are with Cohere and Thinking Machines Lab, the AI startup founded by former OpenAI CTO Mira Murati: → Fluidstack (November 6, 2025): $63.6M over 24 months, or $31.8M/year. → 1,280 B300s, Charlotte (March 15, 2026): $116.1M over 36 months, or $38.7M/year. → 256 H200s, Raleigh (March 16, 2026): $3.7M over 12 months, or $3.7M/year. → Thinking Machines Lab (May 21, 2026): $471.7M over 36 months, or $157.2M/year. → June order, 240 GPU servers (June 8, 2026): $207.6M over 36 months, or $69.2M/year. → July order, 1,536 B300s (July 9, 2026): $222.5M over 48 months, or $55.6M/year. → Cohere (September 30, 2026): $525.6M over 60 months, or $105.1M/year. --- → Total: $1.61B, or $461.3M/year. Unnamed customers are labeled by what they rent, including $NVDA’s current B300 (Blackwell Ultra) and older H200 GPUs. $BRUN’s TCV is over $2.6B, so the other $989M+ is in deals without disclosed terms. The October 6 release calls the $2.6B “total revenue customers have committed to pay,” but the August 14 Q2 deck also counted renewal options and LOIs in TCV, and $BRUN hasn’t said whether the definition changed. So the conservative read counts only the seven contracts with disclosed terms, worth $1.61B, not the $2.6B headline.
@BrokenMoats

Broken Moats on X

Specifically on $DOCU which is approaching levels not witnessed since 2021. Not only is there the rates sensitivity (usually software long duration, higher rates should hurt (been opposite this rate move for now) and the exposure to AI threats (how hard is it to rewire an esignature) even if you want to put those two aside, the business has a significant exposure to the real estate (mortgage, refi, etc) industry and that by all accounts is not performing well (see starts data today, number of existing closings, etc)... seems like this lack of pricing fundamental developments of the business is the tell tale that the move is not based in anything more than a squeeze it would seem. Would love to know from any buyers, why buy here, and what causes you to sell (purely momentum?) It would seem a deep rerating (the opposite from last earnings set up) might be coming for the software trade (especially if AI trade comes back to close out the year). Upsetting they are so inversely correlated, because AI rate of change spending levels does not matter, current AI is enough to present problems for these software providers, at some point that linked should break as AI spend less still won't save software names from their problems

Investor Letters

All letters

Mosaic, Part One: The Story

Mosaic’s history traces the 2004 Cargill-IMC merger and the phosphate and potash mines that shaped NYSE: MOS.

MOS $5.5B
Latticework by MOI Global 15 clicks

Mosaic, Part Two: The Deep Dive

Mosaic, NYSE: MOS, is the subject of a second audio program for professional investors analyzing fertilizer producers.

MOS $5.5B
Latticework by MOI Global 4 clicks

Unicycive (UNCY):

Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical…

UNCY $110M
Triple S Special Situations Investing 4 clicks
UNCY · long

Unicycive Therapeutics INC

Unicycive Therapeutics fell nearly 50% after a second FDA Complete Response Letter tied to a third-party manufacturer for its primary…

UNCY $110M
Value Investors Club

GLOO, part two

Gloo faces related-party deals, insider-heavy IPO ownership, acquisition losses and $84.5 million of CEO-backed puts as it burns cash and…

GLOO $291M
Guardian Research 4 clicks

Why I sold OB pick for 26 SVM

Silvercorp’s falling Ying grades, prolonged GC suspension, El Domo execution risk and Chaarat funding needs weaken its valuation despite…

SVM $2B
The Oak Bloke 27 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 54 of 247

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

90 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.